公开(公告)号：US06596710B1

公开(公告)日：2003-07-22

申请号：US09591911

申请日：2000-06-09

申请人： Richard John Dansereau ,  Russell Youker Mosher ,  Douglas Wayne Axelrod ,  William Kendall Sietsema

发明人： Richard John Dansereau ,  Russell Youker Mosher ,  Douglas Wayne Axelrod ,  William Kendall Sietsema

IPC分类号： A61K31675

CPC分类号： A61K9/2866 ,  A61K9/2846 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/675

摘要： The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.

摘要翻译： 本发明涉及由利塞膦酸酯活性成分组成的新型肠溶衣口服剂型，其包含由利塞膦酸盐活性成分和药学上可接受的赋形剂组成的安全有效量的药物组合物。 所述剂型禁止将利塞膦酸盐活性成分暴露于颊腔，咽，食管和胃的上皮和粘膜组织，从而保护所述组织免受侵蚀，溃疡或其它类似的刺激。 因此，所述剂型影响将所述人或其他哺乳动物的下肠道递送至安全有效量的利塞膦酸盐活性成分，并且基本上减轻了有时伴随利塞膦酸盐活性成分口服的食管炎或食管刺激 。

公开(公告)号：US6096342A

公开(公告)日：2000-08-01

申请号：US303466

申请日：1999-04-30

申请人： Richard John Dansereau ,  Russell Youker Mosher ,  Douglas Wayne Axelrod ,  William Kendall Sietsema

发明人： Richard John Dansereau ,  Russell Youker Mosher ,  Douglas Wayne Axelrod ,  William Kendall Sietsema

IPC分类号： A61K9/28 ,  A61K9/32 ,  A61K9/36 ,  A61K9/50 ,  A61K9/52 ,  A61K31/675 ,  A61K9/14

CPC分类号： A61K9/2866 ,  A61K31/675 ,  A61K9/2846 ,  A61K9/5026 ,  A61K9/5078

摘要： The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.

公开(公告)号：US5935602A

公开(公告)日：1999-08-10

申请号：US820430

申请日：1997-03-12

申请人： Richard John Dansereau ,  Russell Youker Mosher ,  Douglas Wayne Axelrod ,  William Kendall Sietsema

发明人： Richard John Dansereau ,  Russell Youker Mosher ,  Douglas Wayne Axelrod ,  William Kendall Sietsema

IPC分类号： A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K9/32 ,  A61K9/50 ,  A61K9/54 ,  A61K31/675 ,  A61K47/30 ,  A61K47/32 ,  A61K47/38 ,  A61P3/14 ,  A61P5/18 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  A61K9/14

CPC分类号： A61K31/675 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/5026 ,  A61K9/5078

摘要： The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epichelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.

摘要翻译： 本发明涉及由利塞膦酸酯活性成分组成的新型肠溶衣口服剂型，其包含由利塞膦酸盐活性成分和药学上可接受的赋形剂组成的安全有效量的药物组合物。 所述剂型禁止将利塞膦酸酯活性成分暴露于颊腔，咽，食管和胃的上皮和粘膜组织，从而保护所述组织免受侵蚀，溃疡或其它类似的刺激。 因此，所述剂型影响将所述人或其他哺乳动物的下肠道递送至安全有效量的利塞膦酸盐活性成分，并且基本上减轻了有时伴随利塞膦酸盐活性成分口服的食管炎或食管刺激 。